๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS (SNRIs) FOR FIBROMYALGIA SYNDROME

โœ Scribed by Wiffen, Philip J.

Book ID
121000075
Publisher
Informa plc
Year
2013
Tongue
English
Weight
59 KB
Volume
27
Category
Article
ISSN
1536-0288

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Milnacipran: The Clinical Properties of
Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI)
โœ Y. Lecrubier ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 134 KB ๐Ÿ‘ 2 views

Milnacipran is a novel antidepressant agent which selectively inhibits the reuptake of serotonin and noradrenaline without directly aecting postsynaptic receptor sites. The biochemical and pharmacological proยฎle of milnacipran suggested that the drug would be therapeutically eective and well tolerat

Specific serotonin and noradrenaline reu
Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability
โœ M. Briley ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 188 KB ๐Ÿ‘ 2 views

Considerable progress has been made in improving the tolerability of antidepressant drugs. The classical tricyclic antidepressants (TCA) are still, however, the standard for ecacy. The selective serotonin reuptake inhibitors are better tolerated that the tricyclics, but their ecacy in major depressi